Filters

Choose one market

Market access pathways by country

Explore how an innovative medicine moves from approval to patient access.

Selected market

Pakistan

DRAP controls registration and regulated price outputs, while public selection, procurement and hospital access are largely provincial or programme-specific. Insurance and private/self-pay channels remain separate.

DRAP PE&R / Registration Board / local applicant

DRAP/MNHSR&C

company/patient/provider/programme

federal/provincial programme/insurer or hospital clinical-budget authority

Sehat programme/insurer / hospital

8 decision nodes12 cited sources

For education only — not regulatory, pricing or legal advice.

About the content and how to use it

Evidence checked through 2026-08-06A pathway is a decision map—not a launch-time promise

Locate the relevant route first

These choices define how to read the branches below. They do not predict a payer or provider decision.

1

Which Pakistan funding route applies?Provincial public, insurance programme and private channels have different budgets and execution.

Selected routeProvincial public6 applicable nodes

Authorization-to-patient timeline

See the selected route reach the patient

Updates immediately when a choice changes

1

DRAP registration/market authorisationlegal sale and pricing

2

NEML and pricing-category determinationcommercial price and procurement

3

Benefit/package or hospital-use decisionempanelment/procurement

4

Provider empanelment and pre-authorisationhospital treatment

5

Provincial/hospital framework procurementorder and pharmacy stockSelected branch

6

Order, admission and medicine issueclaim/package settlement

7

First funded patientEligible patient + capable provider + authorization + product + clean payment

1Identify province, payer and setting

2Confirm DRAP label and price status

3Secure list/tender or programme approval

4Verify facility budget, stock and patient payment

Do not collapse these decisions

DRAP registration and maximum retail price do not create provincial formulary inclusion, a tender award, programme coverage or hospital stock.

Decision map

What each local node actually produces

Select a row to inspect legal effect and downstream gates

#Local decision / ownerDecision outputDownstream dependencyEvidence

Decision question

Does the product meet quality, safety, efficacy and Pakistan requirements?

Required evidence / materials

CTD/Form 5-F or biologic dossier, GMP, clinical/nonclinical, label/PIL, PV and local licence

Can iterate or branch

standard, priority/accelerated, reliance, appeal, variation/renewal

Source date

PK-S01 · current page；PK-S02 · current guidance

Node linked to cited dossier sourcesProduct/provider execution still requires live verification

Special mechanisms and lifecycle

What can reopen price, coverage or procurement after launch

Dates below come from the cited policy record—not a product forecast

Mechanism / triggerDecision outputIteration / branchPolicy recordLatest observed

Price revisionProvincial tender renewalEssential-list updateProgramme/insurance benefit change

Evidence & policy library

Official basis and policy dates

12 records · checked 2026-08-06